The psychiatrist’s role is to act as a consultant to maximize the likelihood of a successful taper and discontinuation and to minimize collateral morbidities or withdrawal complications. This slideshow features common scenarios in which a planned discontinuation of psychotropic medications occurs.
An overview of select topics in clinical psycho-oncology, including assessment and management of delirium and brain lesions, mood and anxiety disorders, medication adverse effects, and existential death anxiety.
We have medications that can affect serotonin, norepinephrine, and—to a lesser extent—dopamine. Many other neurotransmitters are involved with mood disorders, but we have no medications yet to target them. Neurostimulation offers a non-systemic somatic approach to depression, often with an improved side effect profile. More in this Q&A.
Persons with epilepsy have a higher prevalence of comorbid conditions—psychiatric disorders in particular—than the general population. Here: a look at the most common comorbidities and a discussion of the clinical implications.